Warning letters, 483s, Recalls, Import Alerts, Audit observations
The USFDA has placed Dabur’s Dadra and Nager Haveli facility under Import Alert 66-40 in
Qvents provides useful tools for QMS processes – Risk Assessments, Continuous Process Validations, Supply Chain Traceability
The U.S. FDA has issued a Warning Letter to Simtra BioPharma Solutions following cGMP deviations
The USFDA has issued a Warning Letter to the Indian drug manufacturing facility of Patcos
USFDA Inspection of Pharmathen’s Rodopi facility in Greece (FEI 3009961173) resulted in issuance of Form
FDA has published the USFDA Form 483 issued to sterile drug manufacturing facility of Fareva
In September 2025, the USFDA classified Sun Pharmaceutical Industries Ltd.’s Halol facility as OAI (Official
Author: Venkiteswaran.T.K The USFDA’s 2011 guidance on process validation advocates a life cycle approach and
The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Aspen Biopharma Labs
The USFDA issued a warning letter in January 2025 to Sanofi’s API facility in Framingham,
